Combination Therapy with Nicardipine and Beta‐Adrenergic Blockade for Angina Pectoris

Abstract

Nicardipine a second‐generation dihidropyridine calcium antagonist, has been approved in oral formulation for use in the United States, and is under review for parenteral use. Nicardipine is the most vascular‐selective a‐gent of this class currently approved and should, on theoretical grounds, be ideal for combination therapy with beta‐adrenergic blocking agents. Studies have shown that the combination of nicardipine and beta‐blocking agents offers additional efficacy over monotherapy with either agent alone. The hemodynamic profile of combination therapy appears to be especially favorable in patients with diminished left ventricular function needing therapy with agents of both classes. Adverse effects are few and may be improved compared with other agents of the dihidropyridine class. Copyright © 1992 Wiley Periodicals, Inc.